Amgen's IMDELLTRA Shows Landmark Survival Benefit in Small Cell Lung Cancer
Amgen announced landmark results from its Phase 3 DeLLphi-305 study on extensive stage small cell lung cancer (ES-SCLC) patients. The trial compared IMDELLTRA, a targeted immunotherapy developed by Amgen researchers, in combination with AstraZeneca's Imfinzi, to durvalumab alone.
The results showed a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA combined with Imfinzi. This was the first Phase 3 study including a Bispecific T-cell Engager (BiTE) therapy to demonstrate an overall survival benefit in the first-line maintenance setting for ES-SCLC.
'IMDELLTRA has already revolutionized the standard of survival for patients with extensive stage small cell lung cancer whose disease progressed on or after prior treatment,' said Jay Bradner, M.D., executive vice president at Amgen. 'These landmark results from DeLLphi-305 suggest IMDELLTRA will further revolutionize the standard for survival earlier in the treatment journey.'